UTRS Stock Overview
A commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Minerva Surgical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$1.80 |
| 52 Week Low | US$0.000001 |
| Beta | 59.02 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -100.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Is There An Opportunity With Minerva Surgical, Inc.'s (NASDAQ:UTRS) 44% Undervaluation?
Aug 11
Minerva downgraded at JPMorgan citing lowered guidance
Aug 10Minerva Surgical, Inc. (NASDAQ:UTRS) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 10Minerva Surgical - Uterine Play For Sale
Nov 02Shareholder Returns
| UTRS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -99.0% | 2.7% | 2.8% |
| 1Y | -100.0% | 10.6% | 24.6% |
Return vs Industry: UTRS underperformed the US Medical Equipment industry which returned 10.6% over the past year.
Return vs Market: UTRS underperformed the US Market which returned 24.6% over the past year.
Price Volatility
| UTRS volatility | |
|---|---|
| UTRS Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: UTRS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine UTRS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 174 | Darrin Hammers | minervasurgical.com |
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices.
Minerva Surgical, Inc. Fundamentals Summary
| UTRS fundamental statistics | |
|---|---|
| Market cap | US$8.00 |
| Earnings (TTM) | -US$33.45m |
| Revenue (TTM) | US$51.69m |
0.0x
P/S Ratio0.0x
P/E RatioIs UTRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UTRS income statement (TTM) | |
|---|---|
| Revenue | US$51.69m |
| Cost of Revenue | US$23.69m |
| Gross Profit | US$28.01m |
| Other Expenses | US$61.46m |
| Earnings | -US$33.45m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.77 |
| Gross Margin | 54.18% |
| Net Profit Margin | -64.71% |
| Debt/Equity Ratio | 195.2% |
How did UTRS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 05:26 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Minerva Surgical, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Marcus | J.P. Morgan |
| Danielle Antalffy | Leerink Partners LLC |
| Matthew O'Brien | Piper Sandler Companies |